DoW Peer Reviewed Medical, Impact Award
Summary
The PRMRP Impact Award funds use-inspired, practice-oriented medical research designed to translate basic science into solutions with major near-term potential for patients. Projects must align with specific FY26 congressionally directed PRMRP topic areas and portfolio strategic goals, and may involve multiple PIs under a partnering structure. Awards are typically up to 4 years with total cost caps around $2.8M (single PI) or $3.6M (partnering PI).
Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Impact Award supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from the real-world environment, to foster clinical applicability. The Impact Award intends to translate the fundamental understanding of underlying mechanisms toward solutions that have the potential for major near-term impact for patients and clear alignment to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals.
Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI’s organization will submit a pre-application, but all PIs’ organizations will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $32.0M to fund approximately 10 Impact Award applications with total cost caps of $2.8M for the Single PI Option, or $3.6M for the Partnering PI Option. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Source
Award
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
National Institutes of Health
-
Mission Boost Grants (MBG)
American Cancer Society
-
Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
National Institutes of Health
-
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
National Institutes of Health
-
Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
Food and Drug Administration
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers